Compare The Coca-Cola Co K (KO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Vertex Pharmaceuticals Incorporated — how do they compare? The Coca-Cola Co K trades at $87.76 (market cap $377.63B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: The Coca-Cola Co K is far larger — about 3× Vertex Pharmaceuticals Incorporated's market cap, and The Coca-Cola Co K pays a 2.42% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| KO | VRTX | |
|---|---|---|
Market Cap | $377.63B | $127.55B |
Volume | 14,894,568 | 1,487,944 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $557.96 |
52-Week Low | $66.37 | $407.37 |
Typical Hold Time | 154 Days | 120 Days |
Enterprise Value | $404.81B | $121.68B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $87.97, up 2.51% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong profitability with a 28.56% net income margin and a 44.23% ROE for 2025. Analyst consensus is a Buy with a $95.75 price target, and institutional buying activity is evident in recent news. The stock is positioned near key resistance at $88, with support at $87.
The outlook for KO is positive, driven by consistent earnings performance and a strong dividend history, but risks include high valuation multiples and regional demand volatility. The stock offers stability with growth potential, though investors should monitor debt levels and competitive pressures in the beverage industry.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
